Non-Small Cell Lung Cancer (NSCLC) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Non-Small Cell Lung Cancer (NSCLC) Emerging Therapy and TPP Insights

Thelansis's "Non-Small Cell Lung Cancer (NSCLC) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Non-Small Cell Lung Cancer (NSCLC) Overview

Non-small cell lung cancer (NSCLC) is the predominant form of lung cancer, accounting for approximately 85% of all cases. Around 15-20% are diagnosed at an early stage, where surgical resection, often combined with adjuvant chemotherapy or radiotherapy, offers the best chance of cure. Risk factors can be divided into modifiable and non-modifiable categories. Modifiable risks include tobacco smoking, secondhand smoke, and occupational or environmental exposures such as asbestos, radon, arsenic, chromium, nickel, ionizing radiation, and polycyclic aromatic hydrocarbons. Non-modifiable risks include age, family history, and genetic predisposition. Additionally, prior chest irradiation for malignancies such as breast cancer or Hodgkin lymphoma increases the likelihood of developing NSCLC later in life.

Key Highlights

• In Germany, survival-adjusted prevalent cases of Non-Small Cell Lung Cancer (NSCLC) are projected to increase from 497,473 patients in 2025 to 532,039 patients by 2035, reflecting improved survival outcomes and growing disease burden.
• NSCLC remains the most common subtype of lung cancer, accounting for the majority of lung cancer diagnoses and mortality worldwide.
• Increasing adoption of molecular diagnostics and biomarker testing is enabling broader use of precision oncology approaches in Germany.
• Treatment paradigm has significantly shifted toward targeted therapies and immuno-oncology agents, improving progression-free and overall survival outcomes.
• Persistent unmet need exists in resistant mutations, late-stage diagnosis, metastatic disease progression, and treatment sequencing optimization.
• Growing focus on KRAS, EGFR, ALK, HER2, and PD-(L)1 targeted therapies is expected to further transform the competitive landscape over the forecast period.

Market Overview

• The France NSCLC market is projected to grow from USD 1.3 billion in 2025 to USD 3.2 billion by 2035, indicating strong market expansion driven by innovation in oncology therapeutics.
• Market growth is driven by:
• Rising adoption of premium-priced targeted therapies and immunotherapies
• Increasing biomarker-driven treatment eligibility and personalized medicine approaches
• Improved survival rates leading to longer treatment duration
• Market value is supported by continuous launch of next-generation oncology agents and expanding utilization of combination treatment regimens.
• A robust pipeline of novel targeted therapies, antibody-drug conjugates (ADCs), and next-generation checkpoint inhibitors is expected to create significant commercial opportunities.
• Future growth will depend on advancements in early detection, overcoming therapeutic resistance, and improving long-term survival in advanced and metastatic NSCLC patients.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Pfizer
• Merck Sharp & Dohme LLC
• AstraZeneca
• GlaxoSmithKline
• BeiGene
• Arcus Biosciences, Inc.
• AbbVie
• STCube, Inc.
• Avistone Biotechnology Co., Ltd.
• Regeneron Pharmaceuticals
• Suzhou Zelgen Biopharmaceuticals Co., Ltd.
• Daiichi Sankyo
• Akeso
• Bristol-Myers Squibb
• RemeGen Co., Ltd.
• BioNTech SE
• Hoffmann-La Roche
• Nuvation Bio Inc.
• TJ Biopharma Co., Ltd.
• Klus Pharma Inc.
• Henan Genuine Biotech Co., Ltd.
• Gilead Sciences
• Genentech, Inc.
• Revolution Medicines, Inc.
• Servier Bio-Innovation LLC
• Summit Therapeutics
• Chipscreen Biosciences, Ltd.
• Eli Lilly and Company
• Integro Theranostics
• Amgen
• Tango Therapeutics, Inc.
• Verastem, Inc.
• Nuvalent Inc.
• ArriVent BioPharma, Inc.
• IO Biotech
• Betta Pharmaceuticals Co., Ltd.
• Replimune, Inc.
• ImmunityBio, Inc.